Aykut Kürşat FİDAN, Gülin UÇMAK, Bedriye Büşra DEMİREL, Hülya EFETÜRK, İpek ÖZTÜRK, Semra DEMİRTAŞ ŞENLİK, Burcu ESEN AKKAŞ, İnci ERGÜRHAN İLHAN

The relation between staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patients

Background/aim: The aim of this study was to investigate the contribution of fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in staging of pediatric osteosarcoma patients and also to evaluate the ability of metabolic parameters from the primary tumor to predict tumor necrosis rate (TNR). Material and methods: F-18 FDG-PET/CT imaging was performed in staging 37 pediatric osteosarcoma patients. The metabolic parameters SUVmax (maximum standardised uptake value), MTV (metabolic tumour volume), and TLG (total lesion glycolysis) were measured from the primary tumor. TNR level of the primary tumor was histopathologically measured after standard neoadjuvant chemotherapy treatment. The contribution of F-18 FDG-PET/CT to staging of pediatric osteosarcoma patients and the accuracy of metabolic parameters of the primary tumor to predict TNR were analized by regression analysis. Results: MTV and TLG of the primary tumor were found to efficiently predict histopathologic TNR, whereas SUVmax was not (P = 0.012, P = 0.027, P = 0.25, respectively). Also 5 of 12 patients (41.6%) who were initially defined as localised osteosarcoma were upstaged in consequence of staging F-18 FDG-PET/CT findings. Conclusion: F-18 FDG-PET/CT staging in pediatric osteosarcoma patients can effectively distinguish metastatic-localised disease. MTV and TLG values are important parameters, which can efficiently be used to predict TNR.Key words: Pediatric osteosarcoma, positron emission tomography, tumor necrosis rate

PDF

___

1. Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S et al. Pediatric bone sarcoma: diagnostic performance of 18F-FDG PET/ CT versus conventional imaging for initial staging and followup. American Journal of Roentgenology 2015; 204 (1): 153- 160. doi: 10.2214/AJR.14.12932
2. Quartuccio N, Treglia G, Salsano M, Mattoli MV, Muoio B et al. The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiology and Oncology 2013; 47 (2): 97-102. doi: 10.2478/raon-2013-0017
3. Coffin CM, Lowichik A, Zhou H. Treatment effects in pediatric soft tissue and bone tumors. American Journal of Clinical Pathology 2005; 123 (1): 75-90. doi: 10.1309/h0d4vd760nh6n1r6
4. Costelloe CM, Chuang HH, Madewell JE. FDG PET/CT of primary bone tumors. American Journal of Roentgenology 2014; 202 (6): W521-W531. doi: 10.2214/AJR.13.11833
5. Byun BH, Kong CB, Lim I, Kim BI, Choi CW et al. Comparison of (18) F-FDG PET/CT and (99 m) Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skeletal Radiology 2013; 42 (12): 1673-1681. doi: 10.1007/s00256-013- 1714-4
6. Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. Journal of Nuclear Medicine 2009; 50 (3): 340-347. doi: 10.2967/ jnumed.108.058461
7. Faisham WI, Mat Saad AZ, Alsaigh LN, Nor Azman MZ, Kamarul MI et al. Prognostic factors and survival rate of osteosarcoma: A single‐institution study. Asia-Pacific Journal of Clinical Oncology 2017; 13 (2): e104-e110. doi: 10.1111/ ajco.12346
8. Joo MW, Kang YK, Yoo CY, Cha SH, Chung YG. Prognostic significance of chemotherapy-induced necrosis in osteosarcoma patients receiving pasteurized autografts. PLoS ONE 2017; 12 (2): e0172155. doi: 10.1371/journal. pone.0172155
9. Whelan J, Jinks R, McTiernan A, Sydes M, Hook J et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Annals of Oncology 2012; 23 (6): 1607-1616. doi: 10.1093/annonc/ mdr491
10. National Comprehensive Cancer Network (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Bone Cancer Version 1.2020: 20 [online]. Website: https://www.nccn.org/professionals/physician_gls/pdf/bone. pdf [accessed 08 12 2019].
11. Völker T, Denecke T, Steffen I, Misch D, Schönberger S et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. Journal of Clinical Oncology 2007; 25 (34): 5435-5441. doi: 10.1200/ JCO.2007.12.2473
12. National Comprehensive Cancer Network (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Bone Cancer Version 1.2020: 61 [online]. Website: https://www.nccn.org/professionals/physician_gls/pdf/bone. pdf [accessed 08 12 2019].
13. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL et al. Outcome for adolescent and young adult patients with osteosarcoma. Cancer 2012; 118 (18): 4597-4605. doi: 10.1002/ cncr.27414
14. Davis JC, Daw NC, Navid F, Billups CA, Wu J et al. 18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. Journal of Nuclear Medicine 2018; 59 (1): 25-30. doi: 10.2967/jnumed.117.190595
15. Le Deley MC, Guinebretière JM, Gentet JC, Pacquement H, Pichon F et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. European Journal of Cancer 2007; 43 (4): 752-761. doi: 10.1016/j.ejca.2006.10.023
16. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. Journal of Clinical Oncology 2002; 20 (2): 426-433. doi: 10.1200/JCO.2002.20.2.426
17. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 2013; 266 (2): 388-405. doi: 10.1148/radiol.12110853
18. National Comprehensive Cancer Network (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hodgkin Lymphoma Version 2.2020: 39 [online]. Website: https://www.nccn.org/professionals/physician_gls/pdf/ hodgkins.pdf [accessed 17 04 2020].
19. Oki Y, Chuang H, Chasen B, Jessop A, Pan T et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology 2014; 165 (1): 112-116. doi: 10.1111/bjh.12715
20. National Comprehensive Cancer Network (2020). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). B-Cell Lymphomas Version 1.2020: 135-136 [online]. Website: https://www.nccn.org/professionals/physician_gls/pdf/b-cell. pdf [accessed 22 01 2020].
21. Hawkins DS, Rajendran JG, Conrad EU, Bruckner J, Deary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by F‐18‐fluorodeoxy‐D‐glucose positron emission tomography. Cancer 2002; 94 (12): 3277-3284. doi: 10.1002/ cncr.10599
22. Schulte M, Brecht-Krauss D, Werner M, Hartwig E. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. The Journal of Nuclear Medicine 1999; 40 (10): 1637.
23. Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clinical Nuclear Medicine 2000; 25 (11): 874-881. doi: 10.1097/00003072- 200011000-00004
24. Hawkins DS, Conrad III EU, Butrynski JE, Schuetze S, Meary JF. F‐18‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer: Interdisciplinary International Journal of the American Cancer Society 2009; 115 (15): 3519-3525. doi: 10.1002/cncr.24421
25. Im HJ, Kim TS, Park SY, Min HS, Kim JH et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18 F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. European Journal of Nuclear Medicine and Molecular Imaging 2012; 39 (1): 39-49. doi: 10.1007/s00259- 011-1936-4